Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07085039 · ClinicalTrials.gov registry record · Phase 2
Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease
A Phase 2 study of Castleman's Disease (CD) and Idiopathic Multicentric Castleman's Disease, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT07085039 is a Phase 2 study of Castleman's Disease (CD) and Idiopathic Multicentric Castleman's Disease that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 14 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07085039, a Phase 2 study of Castleman's Disease (CD) and Idiopathic Multicentric Castleman's Disease, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The research study is being done to look at the effects of ruxolitinib in adults with idiopathic Multicentric Castleman Disease (iMCD) that has not gotten better from taking siltuximab or tocilizumab, or who cannot take those medications.
Conditions Studied
Interventions
- DRUG Ruxolitinib
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2025-12-18 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07085039
The ClinicalTrials.gov registry entry for NCT07085039 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Castleman's Disease (CD) appearing as the primary indexed condition, and to 1 intervention - of which Ruxolitinib is the first listed.
NCT07085039 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07085039 about?
NCT07085039 is a clinical study titled "Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease". The research study is being done to look at the effects of ruxolitinib in adults with idiopathic Multicentric Castleman Disease (iMCD) that has not gotten better from taking siltuximab or tocilizumab, or who cannot take those medications.
What is the current status of trial NCT07085039?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2025-12-18. Estimated completion is 2028-12-31.
What conditions does trial NCT07085039 study?
This clinical trial studies the following conditions: Castleman's Disease (CD), Idiopathic Multicentric Castleman's Disease.
What interventions are being tested in trial NCT07085039?
The interventions under investigation include: Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT07085039?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07085039 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Castleman's Disease (CD)
All registered trials for this condition
Idiopathic Multicentric Castleman's Disease
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.